摘要
目的分析探讨血清雌二醇（E2）、5-羟色胺（5-HT）、叶酸以及催乳素（PRL）与围绝经期妇女睡眠质量的相关性。方法选择温州医科大学附属第三医院红十字分院门诊2016年9月～2017年9月收治的围绝经期睡眠质量不佳妇女100例，将其作为研究组，另选取同期本院健康体检正常生育年龄妇女100例作为对照组，应用放射免疫测定法和荧光法对2组妇女的血清E2、5-HT、叶酸以及PRL水平进行测定，并将数据纳入SPSS19.0统计学软件进行多元Logistic回归分析。结果研究组的E2水平、5-HT水平、叶酸水平、PRL水平均显著低于对照组（P＜0.05）；血清E2与睡眠质量的相关系数为1.532，5-HT和叶酸与围绝经期睡眠质量的相关系数分别为0.857和0.396，PRL与睡眠质量相关系数为1.056，血清E2、5-HT、叶酸及PRL都是影响围绝经期睡眠质量的有意义变量，与围绝经期睡眠质量具有相关性。结论血清E2、5-HT、叶酸以及PRL是影响围绝经期妇女睡眠质量的重要因素，E2、5-HT、叶酸以及PRL与围绝经期妇女睡眠质量不佳呈正相关，随着E2、5-HT、叶酸以及PRL水平的降低，围绝经期妇女睡眠质量也会相应降低。
Objective To investigate the correlation between serum estradiol(E2),serotonin(5-HT),folic acid and prolactin(PRL)and sleep quality in perimenopausal women.Methods100cases of perimenopausal women with poor quality of sleep during the period from September2016to September2017were selected as the study group,and the same period was selected as the study group.In the second session of the third Affiliated Hospital of Wenzhou Medical University,the serum E2,5-HT,folic acid and PRL levels of the two groups were determined by radioimmunoassay and fluorescence method,and the data were included in SPSS19.0statistical software for multivariate logistic regression analysis.Results The E2level,5-HT level,folic acid level and PRL level in the study group were significantly lower than those in the control group(P<0.05).The correlation coefficient between serum E2and sleep quality was1.532,The correlation coefficients of sleep quality and5-HT and folic acid were0.857and0.396respectively.The correlation coefficient between PRL and sleep quality was1.056.Serum E2,5-HT,folic acid and PRL were all significant variables affecting the quality of perimenopausal sleep.Conclusion Serum E2,5-HT,folic acid and PRL are important factors affecting the sleep quality of perimenopausal women.E2,5-HT,folic acid and PRL are positively correlated with poor sleep quality in perimenopausal women.With E2,5-HT,folic acid and PRL levels,perimenopausal women,the quality of sleep will be reduced accordingly.
作者
董纯纯
吴雪清
谢兰芬
陈洪亮
胡丽文
DONG Chun-chun;WU Xue-qing;XIE Lan-fen;CHEN Hong-liang;HU Li-wen(Department of Gynecology, the Third Affiliated Hospital, Wenzhou Medical University, Rui’an 325200, China;Department of Gynecology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China;Institute of Red Cross, Third Affiliated Hospital, Wenzhou Medical University, Rui’an 325200, China;Department of Gynecology and Obstetrics, Third Affiliated Hospital, Wenzhou Medical University, Rui’an 325200, China)
出处
《中国生化药物杂志》
CAS
2017年第12期309-311,共3页
Chinese Journal of Biochemical Pharmaceutics
基金
温州科技局计划项目(2017Y0251)
